Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Cocarcinogenesis

rosiglitazone has been researched along with Cocarcinogenesis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Desmond, R; Fischer, SM; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE1

Other Studies

1 other study(ies) available for rosiglitazone and Cocarcinogenesis

ArticleYear
Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
    International journal of cancer, 2008, Nov-15, Volume: 123, Issue:10

    Topics: Animals; Butylhydroxybutylnitrosamine; Carcinogens; Cocarcinogenesis; Female; Immunohistochemistry; PPAR gamma; Rats; Rats, Inbred F344; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms

2008